JP2022510218A5 - - Google Patents
Info
- Publication number
- JP2022510218A5 JP2022510218A5 JP2021530200A JP2021530200A JP2022510218A5 JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5 JP 2021530200 A JP2021530200 A JP 2021530200A JP 2021530200 A JP2021530200 A JP 2021530200A JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133895A JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774111P | 2018-11-30 | 2018-11-30 | |
| US62/774,111 | 2018-11-30 | ||
| US201962794523P | 2019-01-18 | 2019-01-18 | |
| US62/794,523 | 2019-01-18 | ||
| PCT/US2019/063854 WO2020113164A1 (en) | 2018-11-30 | 2019-11-29 | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Division JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510218A JP2022510218A (ja) | 2022-01-26 |
| JP2022510218A5 true JP2022510218A5 (https=) | 2022-12-05 |
| JPWO2020113164A5 JPWO2020113164A5 (https=) | 2022-12-05 |
Family
ID=70853677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530200A Pending JP2022510218A (ja) | 2018-11-30 | 2019-11-29 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220098329A1 (https=) |
| EP (1) | EP3902834A4 (https=) |
| JP (2) | JP2022510218A (https=) |
| AU (1) | AU2019387482A1 (https=) |
| CA (1) | CA3121168A1 (https=) |
| WO (1) | WO2020113164A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US20230248825A1 (en) | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| WO2022032045A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL10Rα/IL2Rγ SYNTHETIC CYTOKINES |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| WO2022056490A1 (en) * | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| CN117794568A (zh) * | 2020-11-18 | 2024-03-29 | 纪念斯隆凯特琳癌症中心 | 抗gpa33多特异性抗体和其用途 |
| US20240059781A1 (en) * | 2021-01-06 | 2024-02-22 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| JP2024519041A (ja) | 2021-05-21 | 2024-05-08 | セレクティス ソシエテ アノニム | 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
| US20240415888A1 (en) * | 2021-10-20 | 2024-12-19 | Memorial Sloan Kettering Cancer Center | Anti-tshr multi-specific antibodies and uses thereof |
| WO2023081818A1 (en) | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| WO2023138579A1 (zh) * | 2022-01-21 | 2023-07-27 | 和铂医药美国股份有限公司 | 抗b7-h7抗体或其抗原结合片段及制备方法和应用 |
| CN114685609B (zh) * | 2022-04-11 | 2023-04-14 | 东北农业大学 | 一种超短自组装抗菌肽fwr及其制备方法与应用 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| CN118146376B (zh) * | 2024-05-09 | 2024-07-05 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| EP2280997A2 (en) * | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| DK3323830T3 (da) * | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| PL2635607T3 (pl) * | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| EP2903691B1 (en) * | 2012-10-05 | 2019-05-22 | F.Hoffmann-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
| TW201444872A (zh) * | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 |
| BR112015023752B1 (pt) * | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
| RU2714733C2 (ru) * | 2013-03-15 | 2020-02-19 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Технологии мультимеризации |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN106459990B (zh) * | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| JP2018520650A (ja) * | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | 新規のポリペプチド |
| JP7269167B2 (ja) * | 2016-10-14 | 2023-05-08 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | モジュラー四価二重特異性抗体プラットフォーム |
| CA3051484A1 (en) * | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
-
2019
- 2019-11-29 WO PCT/US2019/063854 patent/WO2020113164A1/en not_active Ceased
- 2019-11-29 AU AU2019387482A patent/AU2019387482A1/en active Pending
- 2019-11-29 US US17/298,008 patent/US20220098329A1/en active Pending
- 2019-11-29 JP JP2021530200A patent/JP2022510218A/ja active Pending
- 2019-11-29 CA CA3121168A patent/CA3121168A1/en active Pending
- 2019-11-29 EP EP19889678.9A patent/EP3902834A4/en active Pending
-
2024
- 2024-08-09 JP JP2024133895A patent/JP2024174865A/ja active Pending